ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 1640
Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Abstract Number: 1641
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Abstract Number: 1642
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Abstract Number: 1643
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Abstract Number: 1644
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Abstract Number: 1645
Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies